Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% UpsideBenzinga • 08/15/24
Vaxart Provides Business Update and Reports Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/08/24
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8GlobeNewsWire • 08/02/24
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateGlobeNewsWire • 06/13/24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/13/24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersGlobeNewsWire • 04/30/24
Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?InvestorPlace • 04/09/24
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14GlobeNewsWire • 03/07/24
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorGlobeNewsWire • 03/06/24
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 ChallengeGlobeNewsWire • 02/05/24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateGlobeNewsWire • 01/19/24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital ManagementGlobeNewsWire • 01/16/24